About us
Crucell is a global biopharmaceutical company dedicated to bringing meaningful innovation to global health. We do this by discovering, developing, manufacturing and marketing products that combat major threats to the health of people worldwide. Our specialty is fighting infectious diseases—a growing healthcare challenge.
Innovation is the drive force behind our strong research & development (R&D) pipeline, with promising products in pre-clinical and clinical development. Crucell product candidates include flu-mAb, and antibody product effective against a broad range of influenza virus strains, tuberculosis and malaria vaccines, as well as a rabies monoclonal antibody combination-all produced on our unique PER.C6® human-cell technology.
Currently we are combating twelve major infectious diseases with our range of marketed vaccines in the paediatric, travel & endemic and respiratory fields. We are the largest independent vaccine company in the world.
The combination of our innovative technologies and creative minds drives Crucell’s success, which we measure in human and business terms.
Headquartered in Leiden, the Netherlands, Crucell currently employs over 1300 people and has offices in China, Indonesia, Italy, Korea, Malaysia, Spain, Sweden, Switzerland, the UK the USA and Vietnam. Crucell N.V. is listed on NYSE Euronext and NASDAQ (CRXL) and the SIX Swiss Exchange (CRX).
Broad development pipeline
Crucell has a broad development pipeline, including vaccines and antibody products. Several Crucell products are based on our unique PER.C6® production technology. Crucell licenses this and other cutting edge technologies to the biopharmaceutical industry. Important partners and licensees are Johnson & Johnson, DSM Biologics, Novartis, sanofi aventis, MedImmune, GSK, CSL, Merck and Wyeth.
Robust product portfolio
Our vaccine business provides stable and predictable sales and cash flow. In 2009, we sold more than 115 million vaccine doses in over 100 countries throughout the world, which makes us the largest independent vaccine player. Within vaccines we operate in three main markets: paediatric, travel & endemic, and respiratory.
Paediatric:
| - | Fully liquid vaccine for protection against five childhood diseases | |
| - | Recombinant hepatitis B vaccine | |
| - | Vaccine for protection against measles and rubella (all age groups) | |
| - | Low dosage unique aluminum-free hepatitis A vaccine (0.25ml) | |
Travel & Endemic:
| - | Aluminum-free hepatitis A vaccine | |
| - | Oral typhoid vaccine | |
| - |
Internationally licensed oral vaccine with documented efficacy against diarrhea caused by cholera | |
Respiratory:
| - | Virosomal adjuvanted influenza (all age groups) |
E-MAIL THIS PAGE
PRINT THIS PAGE